N
APGE icon

Natixis’s Apogee Therapeutics APGE Stock Holding History

Natixis’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$165K Buy
+1,241
New +$112K ﹤0.01% 957

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Natixis's APGE Position: Q2 2026 in Review

Natixis opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 1,241 shares worth $165K. The stake represents ﹤0.01% of the portfolio and ranks #957 among its holdings.

288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Natixis held 1,241 shares of Apogee Therapeutics worth $165K as of Q2 2026.
  • Apogee Therapeutics was a new Natixis position in Q2 2026.
  • Apogee Therapeutics made up ﹤0.01% of Natixis's portfolio in Q2 2026, its #957 holding.
  • 288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.